Institute of Cardiology, Catholic University of Sacred Heart, Rome, Italy.
EuroIntervention. 2012 Oct;8(6):701-7. doi: 10.4244/EIJV8I6A109.
Restenosis and bifurcated lesions represent technically challenging lesions for percutaneous coronary interventions (PCI). Data regarding procedural and clinical outcome of re-PCI for restenosis of stented bifurcated lesions are lacking. Our aims were to evaluate angiographic and procedural results and one-year clinical outcome of PCI for restenosis of stented bifurcated lesions.
Consecutive patients undergoing PCI for restenosis of one bifurcated lesion previously treated by stent implantation at our centre entered the study. The primary endpoint was angiographic and procedural success, defined as final residual stenosis ≤30% in the main vessel with TIMI 3 flow in both MV and side branch, and stenosis ≤50% in the SB without death, myocardial infarction or target vessel revascularisation during hospitalisation. The secondary endpoint was the incidence of major adverse cardiac events at one-year clinical follow-up. The study population included 64 patients treated by PCI on a single restenotic bifurcated lesion. Angiographic and procedural success was achieved in 61 cases (95.3%) whereas the three cases of failure were due to SB residual stenosis >50%. At one year, MACE rate was 18.7% (12/64) with rates of cardiac death, MI and TVR of 1.6% (1/64), 6.2% (4/64) and 18.7% (12/64), respectively. No cases of stent thrombosis occurred. Patients treated by a single drug-eluting stent (DES) on main vessel (MV) had a significant lower rate of MACE at one year as compared to patients treated with balloon only PCI or by double-stenting technique or with a BMS, irrespective of the strategy adopted: 4/37 (10.8%) vs. 8/27 (29.6%); p=0.04.
PCI in restenotic bifurcated lesions can be a good treatment option with high rates of angiographic and procedural success and an acceptable rate of long-term MACE. The use of a single DES implantation may be a promising strategy as it is associated with lower rates of MACE in the long term.
再狭窄和分叉病变是经皮冠状动脉介入治疗(PCI)的技术难题。目前缺乏关于支架内再狭窄分叉病变再 PCI 的治疗方法和临床结果的数据。本研究旨在评估 PCI 治疗支架内再狭窄分叉病变的血管造影和手术结果以及 1 年临床结果。
本研究连续纳入了在我院因支架内再狭窄而接受 PCI 治疗的分叉病变患者。主要终点是血管造影和手术成功,定义为主支的最终残余狭窄率≤30%,同时主支和分支均达到 TIMI 3 级血流;分支的狭窄率≤50%,且住院期间无死亡、心肌梗死或靶血管血运重建。次要终点是 1 年临床随访时主要不良心脏事件的发生率。研究人群包括 64 例接受单支再狭窄分叉病变 PCI 治疗的患者。61 例(95.3%)患者达到了血管造影和手术成功,3 例失败的原因是分支残余狭窄率>50%。1 年时,MACE 发生率为 18.7%(12/64),其中心源性死亡、心肌梗死和 TVR 的发生率分别为 1.6%(1/64)、6.2%(4/64)和 18.7%(12/64)。无支架血栓形成病例。与单纯球囊 PCI 或双支架技术或使用 BMS 治疗的患者相比,主支(MV)仅植入 1 枚药物洗脱支架(DES)的患者 1 年时 MACE 发生率显著降低:4/37(10.8%)vs. 8/27(29.6%);p=0.04。
PCI 治疗支架内再狭窄分叉病变是一种较好的治疗选择,具有较高的血管造影和手术成功率,长期 MACE 发生率可接受。使用单枚 DES 植入可能是一种有前途的策略,因为它与长期较低的 MACE 发生率相关。